Becton Dickinson and Co (BDX) Holdings Boosted by Vestor Capital LLC

Vestor Capital LLC boosted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 15.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 68,214 shares of the medical instruments supplier’s stock after acquiring an additional 9,102 shares during the quarter. Becton Dickinson and accounts for approximately 3.3% of Vestor Capital LLC’s portfolio, making the stock its 8th largest position. Vestor Capital LLC’s holdings in Becton Dickinson and were worth $15,370,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in BDX. FIL Ltd boosted its holdings in shares of Becton Dickinson and by 22.3% during the third quarter. FIL Ltd now owns 105,400 shares of the medical instruments supplier’s stock worth $27,510,000 after acquiring an additional 19,240 shares during the period. CIBC World Markets Inc. boosted its holdings in shares of Becton Dickinson and by 6.9% during the third quarter. CIBC World Markets Inc. now owns 33,508 shares of the medical instruments supplier’s stock worth $8,746,000 after acquiring an additional 2,169 shares during the period. Trexquant Investment LP bought a new stake in shares of Becton Dickinson and during the third quarter worth approximately $525,000. Schroder Investment Management Group boosted its holdings in shares of Becton Dickinson and by 34.4% during the third quarter. Schroder Investment Management Group now owns 50,601 shares of the medical instruments supplier’s stock worth $13,207,000 after acquiring an additional 12,963 shares during the period. Finally, Holderness Investments Co. boosted its holdings in shares of Becton Dickinson and by 21.6% during the third quarter. Holderness Investments Co. now owns 1,436 shares of the medical instruments supplier’s stock worth $375,000 after acquiring an additional 255 shares during the period. 84.80% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BDX stock traded down $0.18 during trading on Monday, hitting $239.94. The company had a trading volume of 156,653 shares, compared to its average volume of 1,025,902. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83. The stock has a market cap of $64.61 billion, a P/E ratio of 21.79, a price-to-earnings-growth ratio of 1.69 and a beta of 1.21. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $265.87.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.58 by $0.12. The business had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.48 earnings per share. Analysts forecast that Becton Dickinson and Co will post 12.1 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Investors of record on Friday, March 8th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.28%. The ex-dividend date is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.

In other Becton Dickinson and news, EVP Ribo Alberto Mas sold 4,808 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $255.03, for a total transaction of $1,226,184.24. Following the completion of the sale, the executive vice president now directly owns 22,476 shares in the company, valued at $5,732,054.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vincent A. Forlenza sold 3,123 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $796,458.69. Following the sale, the chief executive officer now owns 215,372 shares of the company’s stock, valued at $54,926,321.16. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,684 shares of company stock valued at $7,518,574. 0.12% of the stock is currently owned by corporate insiders.

A number of brokerages have recently issued reports on BDX. Raymond James reduced their price objective on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a report on Tuesday, March 19th. UBS Group began coverage on Becton Dickinson and in a report on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price objective for the company. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Wednesday, February 6th. Finally, Piper Jaffray Companies boosted their price objective on Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a report on Tuesday, February 5th. Five equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $255.75.

ILLEGAL ACTIVITY NOTICE: This story was reported by WKRB News and is the property of of WKRB News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.wkrb13.com/2019/03/25/becton-dickinson-and-co-bdx-holdings-boosted-by-vestor-capital-llc.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: What is a portfolio manager?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.